News

Video

EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Author(s):

Terence Friedlander, MD

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Related Videos
Roger Li, MD,
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
Antonio Cigliola, MD
Rohan Garje, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Brian I. Rini, MD, FASCO
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
Laurence Albigès, MD, PhD
utinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis
Related Content
Darrin Beaupre, MD, PhD
July 15th 2024

IDE937 Generates Responses in NSCLC and Urothelial Cancer Harboring MTAP Deletions

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Maha H.A. Hussain, MD, FACP, FASCO
July 8th 2024

Tazemetostat Plus Pembrolizumab Is Tolerable in Advanced Urothelial Carcinoma

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Bradley McGregor, MD
June 26th 2024

Sacituzumab Govitecan/Enfortumab Vedotin ± Pembrolizumab Under Investigation in Metastatic Urothelial Carcinoma

Thomas Powles, MD
June 25th 2024

Perioperative Durvalumab Plus Chemo Meets EFS, OS End Points in MIBC